alendronate has been researched along with phosphorus in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (28.13) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 7 (21.88) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Dubois, SK; Pak, CY; Roberts, ML; Ruml, LA | 1 |
| Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M | 1 |
| Azuma, Y; Higuchi, O; Hirata, N; Kiyoki, M; Sugimoto, I; Tsuchimoto, M; Yamamoto, I | 1 |
| Ammann, P; Bonjour, JP; Budayr, AA; Burckhardt, P; Gertz, B; Jaquet-Müller, F; Jenzer, A; Rizzoli, R; Thiébaud, D; Zysset, E | 1 |
| Bagdon, W; Guy, J; Hayes, WC; Kline, WF; Peter, CP; Shea, M | 1 |
| Fukunaga, M; Inoue, T; Kaneda, K; Kishimoto, H; Kushida, K; Minaguchi, H; Nagata, Y; Nakashima, M; Orimo, H; Shiraki, M; Tomita, A | 1 |
| Asplin, J; Bushinsky, DA; Krieger, NS; Neumann, KJ | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 1 |
| Gnudi, S; Malavolta, N; Ripamonti, C; Veronesi, M; Zanardi, M | 1 |
| Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M | 1 |
| Fukunaga, M; Inoue, T; Kaneda, K; Kishimoto, H; Kushida, K; Morii, H; Nakamura, T; Nakashima, M; Orimo, H; Shiraki, M; Yamamoto, K | 1 |
| Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M | 3 |
| Cavallo, A; Colarusso, S; Costa, L; Di Micco, L; Fittipaldi, MR; Fonderico, F; Lupoli, G; Lupoli, GA; Paglione, A; Panico, A | 1 |
| Capar, M; Köşüş, A; Köşüş, N | 1 |
| Iwamoto, J; Sato, Y; Seki, A; Takeda, T; Yamada, H; Yeh, JK | 1 |
| Enishi, T; Kobayashi, T; Mitsuhashi, T; Miyamoto, M; Nishioka, T; Tamura, T; Yagi, S | 1 |
| Akçay, A; Bavbek, N; Inegöl, I; Kanbay, M; Turgut, FH; Uz, E; Yanik, B; Yanik, T | 1 |
| Andresen, CJ; Bagi, CM; Berryman, E; Hanson, N; Moalli, M; Olson, E; Shen, V; Volberg, M | 1 |
| Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M | 1 |
| Brown, IN; Cohen, A; Fleischer, JB; Hershman, DL; Joe, AK; Johnson, MK; McMahon, DJ; Silverberg, SJ | 1 |
| Alon, US; Freundlich, M | 1 |
| Chen, X; Dong, H; Fang, L; Hu, Q; Li, Y; Li, Z; Mao, C; Miao, G | 1 |
| Almalki, AL; Elshal, MF; Hussein, HK; Khan, JA | 1 |
| Kaji, H; Kawao, N; Okada, K; Okumoto, K; Tamura, Y; Yano, M | 1 |
| Gonçalves, RV; Maldonado, IRSC; Novaes, RD; Oliveira, MGA; Oliveira, TT; Pinto, AS; Sequetto, PL | 1 |
| Filella, X; Florez, H; Guañabens, N; Mandelikova, S; Monegal, A; Peris, P | 1 |
| Deng, J; Feng, Z; Li, Q; Li, Y; Pan, T; Zhao, C | 1 |
| Iba, K; Sonoda, T; Takada, J; Yamashita, T | 1 |
| Di Bonito, M; Ferretti, V; Giampà, E; Nuvoli, G; Paoletti, F; Piazzini, M; Ranieri, M; Tuveri, MA; Vinicola, V | 1 |
| Campelo, AE; Cutini, PH; Massheimer, VL | 1 |
13 trial(s) available for alendronate and phosphorus
| Article | Year |
|---|---|
Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate.
Topics: Adult; Alendronate; Bed Rest; Biomarkers; Bone and Bones; Bone Density; Calcium; Diphosphonates; Double-Blind Method; Humans; Hydroxyproline; Immobilization; Male; Parathyroid Hormone; Phosphorus; Urinary Calculi | 1995 |
A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Bone Diseases, Metabolic; Calcium; Female; Humans; Japan; Kinetics; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Placebos | 1998 |
Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
Topics: Aged; Alendronate; Calcitriol; Calcium; Calcium Channel Agonists; Calcium, Dietary; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus | 1999 |
Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Back Pain; Bone Density; Calcium; Collagen; Collagen Type I; Etidronic Acid; Female; Humans; Incidence; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pain Measurement; Peptides; Phosphorus; Radiography; Spinal Fractures | 2003 |
Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Calcium; Female; Follow-Up Studies; Humans; Incidence; Japan; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Phosphorus; Radiography; Spinal Fractures | 2004 |
Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Calcium; Collagen; Collagen Type I; Female; Humans; Incidence; Japan; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Phosphorus; Spinal Fractures | 2004 |
Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Back Pain; Bone Density; Bone Remodeling; Calcium; Chronic Disease; Exercise; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Vibration | 2005 |
[Methimazole versus methimazole and diphosphonates in hyperthyroid and osteoporotic patients].
Topics: Aged; Alendronate; Alkaline Phosphatase; Antithyroid Agents; Bone Density; Calcium; Case-Control Studies; Drug Therapy, Combination; Humans; Hyperthyroidism; Male; Methimazole; Osteoporosis; Parathyroid Hormone; Phosphorus; Treatment Outcome | 2005 |
Cyclical alendronate treatment in postmenopausal women with osteoporosis.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Phosphorus | 2005 |
Alendronate inhibits periprosthetic bone loss around uncemented femoral components.
Topics: Aged; Alendronate; Amino Acids; Bone Cements; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Female; Femur; Humans; Male; Middle Aged; Phosphorus; Prostheses and Implants | 2007 |
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Raloxifene Hydrochloride; Risedronic Acid; Uric Acid | 2007 |
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Calcium; Female; Fractures, Bone; Humans; Lipid Metabolism; Osteoporosis; Phosphorus; Raloxifene Hydrochloride; Spine | 2008 |
Prevention of bone loss after withdrawal of tamoxifen.
Topics: Absorptiometry, Photon; Administration, Oral; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Serum Albumin; Substance Withdrawal Syndrome; Tamoxifen; Treatment Outcome | 2008 |
19 other study(ies) available for alendronate and phosphorus
| Article | Year |
|---|---|
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotopes; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Etidronic Acid; Hydroxycholecalciferols; Hypercalcemia; Male; Organ Culture Techniques; Osteoclasts; Pamidronate; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Tibia; Tissue Distribution | 1995 |
Alendronate modulates osteogenesis of human osteoblastic cells in vitro.
Topics: Alendronate; Alkaline Phosphatase; Base Sequence; Bone Matrix; Calcium; Cells, Cultured; Child; Collagen; Diphosphonates; DNA; Gene Expression; Humans; Male; Molecular Sequence Data; Osteoblasts; Osteocalcin; Osteogenesis; Phosphorus; Polymerase Chain Reaction; Protein Biosynthesis | 1994 |
Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Topics: Alendronate; Calcitriol; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Male; Neoplasms; Pamidronate; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Phosphorus; Proteins | 1994 |
Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
Topics: Administration, Oral; Alendronate; Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Calcium; Diphosphonates; Dogs; Drug Evaluation, Preclinical; Female; Male; Organ Size; Phosphorus; Time Factors | 1996 |
Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium Oxalate; Calcium Phosphates; Calcium, Dietary; Creatinine; Disease Models, Animal; Female; Humans; Kidney Calculi; Magnesium; Male; Phosphorus; Quaternary Ammonium Compounds; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley | 1999 |
[A study of the safety of rapid infusion of alendronate].
Topics: Alendronate; Blood Urea Nitrogen; Bone Neoplasms; Breast Neoplasms; Calcium; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Phosphorus | 1999 |
Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Calcium; Collagen; Collagen Type I; Female; Humans; Japan; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Phosphorus; Time Factors | 2005 |
Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats.
Topics: Alendronate; Amino Acids; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcium; Female; Hydroxycholecalciferols; Osteocalcin; Ovariectomy; Phosphorus; Rats; Rats, Sprague-Dawley; Tibia | 2006 |
Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
Topics: Absorptiometry, Photon; Aging; Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Calcium; Callithrix; Disease Models, Animal; Female; Humans; Male; Osteogenesis; Osteoporosis; Phosphorus | 2007 |
Bisphosphonates in children with hypercalciuria and reduced bone mineral density.
Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Child; Creatinine; Diphosphonates; Female; Humans; Hypercalciuria; Imidazoles; Male; Phosphorus; Retrospective Studies; Zoledronic Acid | 2008 |
Investigation of emulsified, acid and acid-alkali catalyzed mesoporous bioactive glass microspheres for bone regeneration and drug delivery.
Topics: Acids; Alendronate; Alkalies; Biocompatible Materials; Body Fluids; Bone Regeneration; Calcium; Catalysis; Ceramics; Drug Delivery Systems; Emulsions; Glass; Humans; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Microscopy, Electron, Scanning; Microspheres; Nitrogen; Particle Size; Phosphorus; Porosity; Silicon; Spectroscopy, Fourier Transform Infrared; Temperature; Thermogravimetry; X-Ray Diffraction | 2013 |
Synergistic antiosteoporotic effect of Lepidium sativum and alendronate in glucocorticoid-induced osteoporosis in Wistar rats.
Topics: Alendronate; Animals; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Calcium; Disease Models, Animal; Drug Synergism; Female; Femur; Glucocorticoids; Lepidium sativum; Osteoporosis; Phosphoric Monoester Hydrolases; Phosphorus; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Tibia | 2013 |
Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Topics: Activin Receptors, Type I; Alendronate; Alkaline Phosphatase; Animals; Benzamides; Calcium; Cell Line; Collagen Type I; Dioxoles; Imidazoles; Male; Mice; Mice, Nude; Mutation; Myoblasts; Myositis Ossificans; Ossification, Heterotopic; Osteoclasts; Peptides; Phosphorus; Pyridines | 2016 |
Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcium; Dexamethasone; Drug Synergism; Osteoporosis; Phosphorus; Rats; Rats, Wistar; Simvastatin; Urea | 2017 |
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibrous Dysplasia of Bone; Humans; Male; Middle Aged; Osteomalacia; Pamidronate; Phosphorus; Reference Values; Young Adult; Zoledronic Acid | 2018 |
Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Becaplermin; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Phosphorus; Procollagen; Teriparatide; Treatment Outcome; Triglycerides; Vascular Endothelial Growth Factor A | 2018 |
Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; Calcium; Collagen Type I; Diphosphonates; Female; Humans; Japan; Osteoporosis; Osteoporosis, Postmenopausal; Peptides; Phosphorus; Retrospective Studies; Risedronic Acid; Tartrate-Resistant Acid Phosphatase; Time Factors; Treatment Outcome | 2020 |
Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Calcifediol; Calcium; Cholecalciferol; Drug Therapy, Combination; Exercise; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Retrospective Studies; Vitamin D | 2019 |
Vascular response to stress: Protective action of the bisphosphonate alendronate.
Topics: Alendronate; Calcium; Diphosphonates; Endothelial Cells; Humans; Lipopolysaccharides; Mitogen-Activated Protein Kinases; Phosphorus; Protein Kinase C; Vascular Endothelial Growth Factor A | 2022 |